<DOC>
	<DOC>NCT02324049</DOC>
	<brief_summary>To evaluate the safety and tolerability of intravenous (IV) administration of SBC 103 in subjects with mucopolysaccharidosis III, type B (MPS IIIB, Sanfilippo B) with evaluable signs or symptoms of developmental delay.</brief_summary>
	<brief_title>Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in MPS IIIB</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis III</mesh_term>
	<criteria>Key Patient will be greater than or equal to 2 years of age but less than 12 years of age at the time of informed consent. Definitive diagnosis of MPS IIIB. Documented developmental delay Key Received treatment with gene therapy at any time Previous hematopoietic stem cell or bone marrow transplant. Has any internal or nonremovable external metal items that may present a safety risk for study assessments that utilize magnetic fields, or any other medical condition or circumstance in which an MRI is contraindicated according to local institutional policy. Known hypersensitivity to eggs.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MPS IIIB</keyword>
	<keyword>Mucopolysaccharidosis</keyword>
	<keyword>Mucopolysaccharidosis type IIIB</keyword>
	<keyword>Sanfilippo Syndrome</keyword>
	<keyword>Metabolism, Inborn Errors</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Genetic Diseases, Inborn</keyword>
	<keyword>Carbohydrate Metabolism, Inborn Errors</keyword>
	<keyword>Connective Tissue Diseases</keyword>
	<keyword>Lysosomal Storage Diseases</keyword>
	<keyword>Mucinoses</keyword>
	<keyword>Mucopolysaccharidoses</keyword>
	<keyword>Pathologic Processes</keyword>
</DOC>